Advicenne SA
0.67
EUR
0.00
(0.00%)
Advicenne SA
GETTEX:3MM
(Gettex)
Recent
price
0.67
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Advicenne S.A. is a specialty pharmaceutical company focused on developing, commercializing, and marketing innovative treatments for rare renal diseases and niche neurological indications. Founded in 2007 and headquartered in Paris, France, the company offers a portfolio that includes Sibnayal (ADV7103), a treatment for metabolic disorders, distal renal tubular acidosis (dRTA), and cystinuria; Likozam, a formulation of clobazam for managing severe anxiety-related conditions; and Levidcen, a galenic form of levetiracetam for treating epileptic seizures. Advicenne targets pediatric and adult patients with orphan nephrology diseases and operates primarily in Europe, the Middle East, and has plans for expansion into the United States. The company holds marketing authorizations in several European countries for its products and has ongoing late-stage clinical development, including pivotal Phase III trials in North America. Recent major developments include the receipt of marketing authorization and reimbursement for Sibnayal in Saudi Arabia and increased market penetration reflected in a 103% sales growth of Sibnayal in Europe and the Middle East in 2025. The company reported a 13% increase in total revenues for the first half of 2025, driven largely by Sibnayal sales growth. Advicenne also conducted a capital increase of 2.6 million euros, extending its financial visibility through the end of 2026, and is preparing a marketing authorization application for ADV7103 in the United States planned for the fourth quarter of 2025. These actions support Advicenne’s strategic expansion and commercialization efforts in orphan renal disease markets, emphasizing innovation and unmet medical needs in both pediatric and adult patient populations. The company is listed on Euronext Paris (Ticker: ALDVI.PA) and continues to build its presence internationally.